Programmed Death-Ligand 1 (PD-L1) Expression in Patients with Primary or Secondary Myelofibrosis

• DOI: 10.22541/au.169688244.48985917/v1
• Publication Date: 2023-10-09T20:14:17Z
• Authors: Francisco Socola; Moayed Ibrahim; Catherine Murphree; Kirtesh Patel; Matthew Mastrodom...; Nakhle S. Saba; Hana Safah; Janet Schmid

It has been described in mice models that Primary Myelofibrosis (PMF) with JAK2-V617F mutation an increased expression of programmed death-ligand 1 (PD-L1) megakaryocytes leading to cancer immune evasion by inhibiting the T-lymphocytes. To prove this hypothesis, we quantified PD-L1 on 29 bone marrow (BM) biopsies. We created a scoring system quantify megakaryocytes. obtained 14 BM JAK2 positive PMF, 5 negative PMF and 10 patients normal was higher group compared control score 212.6 vs 121.1 (t-value 2.05,p-value 0.025). In addition, regardless mutational status when 205.9 121.1(t-value 2.12,p-value 0.021). There no difference between 187.2 1.02,p-value 0.162). These findings suggest have group. postulate combination checkpoint inhibitors may be active treatment option mutated given expression.